SCHEMBL10127399

SCHEMBL10127399

CCc1nc(C(N)=O)c(Nc2cccc(N3CCN(C)CC3)c2)nc1Cl

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EML4 Q9HC35 10/20 0.69
ALK Q9UM73 10/20 0.69
EGFR P00533 6/20 0.54
ROS1 P08922 5/20 0.54
FLT3 P36888 5/20 0.54
RET P07949 4/20 0.54
CDK2 P24941 2/20 0.51
AURKA O14965 1/20 0.51
CCNT1 O60563 1/20 0.51
CDK4 P11802 1/20 0.51
CCND1 P24385 1/20 0.51
CDK9 P50750 1/20 0.51
CDK6 Q00534 1/20 0.51
CDK11A Q9UQ88 1/20 0.51
PLK4 O00444 1/20 0.48
CHEK1 O14757 1/20 0.48
PRKD3 O94806 1/20 0.48
LCK P06239 1/20 0.48
CSF1R P07333 1/20 0.48
KIT P10721 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10127559 0.91 EML4 (0.64) EML4ALKEGFRROS1FLT3
SCHEMBL10127810 0.89 EML4 (0.61) EML4ALKEGFRROS1FLT3
SCHEMBL10127728 0.88 EML4 (0.54) EML4ALKEGFRROS1FLT3
SCHEMBL17690575 0.88 EML4 (0.55) EML4ALKEGFRROS1FLT3
SCHEMBL10127376 0.88 EML4 (0.67) EML4ALKEGFRROS1FLT3
SCHEMBL10127766 0.87 EML4 (0.58) EML4ALKEGFRROS1FLT3
SCHEMBL10127532 0.86 EGFR (0.54) EML4ALKEGFRROS1FLT3
SCHEMBL10126788 0.85 EML4 (0.59) EML4ALKEGFRROS1FLT3
SCHEMBL17689760 0.84 EML4 (0.51) EML4ALKEGFRROS1FLT3
SCHEMBL15134661 0.84 EML4 (0.63) EML4ALKEGFRROS1FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9487491-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2016-11-08 US disclosed
US-9487491-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2016-11-08 US disclosed
US-8969336-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2015-03-03 US disclosed
US-8969336-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2015-03-03 US disclosed
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2014-12-18 US disclosed
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2014-12-18 US disclosed
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND WATERS TECHNOLOGIES CORPORATION (US) 2012-02-16 US disclosed
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND WATERS TECHNOLOGIES CORPORATION (US) 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND EML4, ALK, ERBB4 EML4 1/4885ALK 2/4885EGFR 28/4885
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND EML4, ALK, ERBB4 EML4 1/4885ALK 2/4885EGFR 28/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.